Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.>
You can use a suffix operator (*) as the placeholder for end of a term. The query must start with at least one alphanumeric character before the suffix operator. E.g., Rifam* will get you “Rifampicin” and “Rifampin”. For more advanced searching tips click here.
Brand Name(s) include: N/A
Disease: Malaria
Drug Class: Antimalarials
Date Updated: June 2021
Related Files: Amodiaquine (parent drug)
Absorption Model |
|
Volume of Distribution |
|
Route of Elimination |
|
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
Brand Name(s) include: Coartem (artemether, lumefantrine), Riamet (artemether, lumefantrine)
Disease: Malaria
Drug Class: Antimalarials
Related Files: Artemether – drug partner in fixed dose combinations
Date Updated: December 2022
Absorption Model |
|
Volume of Distribution Details |
Note: Kp scalar and Kp adipose used |
Route of Elimination |
CYP3A4 (40%); non-specific hepatic metabolism (60%) |
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
Prepared: June 2023 The RES-Fostamatinib-R406_V21 model has been developed primarily as inhibitor of intestinal BCRP using the New GI physiology in Simcyp V21 with altered GI tract population inputs that became default in V22. Fostamatinib rapidly cleaved (hydrolyzed) to R406 (active moiety) in the gut by alkaline phosphatases. Thus, the Fit-for-purpose file with an in vivo CL/F is modelling the metabolite and not the parent. The verification was performed for 100-150 mg SD and BID. The Rosuvastatin DDI uses 100 mg BID. Example workspaces for the metabolite PK and the DDI with Rosuvastatin are attached. The BCRP component of Rosuvastatin (V21 using the New GI physiology) was optimised using Eltrombopag and then verified with other BCRP-Inhibitors available on the members area or within the Simcyp Simulator, see attached ‘BCRP-Inhibitor V21’ document for details.
The RES-Chlorzoxazone file was primarily developed as an inhibitor of CYP3A4. This document provides: 1. Examples of model performance 2. A summary of the key pharmacokinetic features of Chlorzoxazone considered within the model.
28 |